Blood test may spot lung cancer recurrence months before scans

NCT ID NCT07257471

Recruiting now Knowledge-focused Sponsor: Beijing Haidian Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether measuring DNA methylation markers in the blood can predict if lung cancer will come back after a minimally invasive treatment called Co-ablation. Researchers will follow 30 patients with early-stage non-small cell lung cancer who cannot have surgery. Blood samples will be taken before treatment and up to 24 months after to see if the markers can detect recurrence earlier than standard imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Co-ablation system therapy
What this could lead to: If successful, this could lead to a simple blood test that detects lung cancer recurrence earlier than scans, helping doctors personalize follow-up care.
What could go wrong: This is a small, early study with only 30 participants, so results may not apply to everyone. The methylation test may not be accurate enough to replace standard monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER (NSCLC)

Contacts and locations

Locations

Beijing Haidian Hospital
RECRUITING

Beijing, Beijing Municipality, 100080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.